Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 327

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 327
---
uant to the efficacy program, the overall amount aimed to be saved under this subject is estimated at $72,000 Impact on Research and Development (R&D) ExpensesFor the six months ended June 30, 2024, research and development expenses totaled $410,395, reflecting a significant decrease of $638,881 (60.9%) from $1,049,276 during the six months ended June 30, 2023. The primary contributors to this reduction were: • Workforce Reduction— Decreased personnel costs resulting from the downsizing of R&D staff. The R&D workforce reduction is estimated to save $452,000. • Reduction in External Research Services— Reduced expenditures on third -partyresearch contracts and consultants. The reduction in R&D external research services is estimated at $37,000. • Lower Laboratory Operational Costs— Streamlined research activities led to a decrease in material costs and laboratory maintenance expenses. The reduction in R&D laboratory operational costs is estimated at $129,600. Impact on General and Administrative (G&A) ExpensesGeneral and administrative expenses for the six months ended June 30, 2024, were $376,286, a decline of $302,166 (44.5%) from $678,452 in the six months ended June 30, 2023. The reduction was achieved through: • Personnel Cost Savings— Decreased salaries and benefits for administrative staff due to layoffs. The G&A personnel cost savings are estimated at $166,500. • Reduced Overhead and Office Expenses— Cost -cuttinginitiatives such as office space downsizing and renegotiated leases. The G&A overhead reduction is estimated to save $33,333. • Elimination of Discretionary Spending— Lower legal, accounting, and other professional service expenses as part of overall budgetary control measures. The planned elimination or lowering of the various professional services is estimated to save $77,500. 177 Kadimastem’s efficiency program resulted in substantial cost reductions in R&D and G&A expenses, contributing to a lower overall operating loss. The company strategically implemented workforce reductions, optimized service provider contracts, and curtailed discretionary spending to align with a leaner operational model. These measures led to a total expense reduction of over $1.1 million across both R&D and G&A categories, enabling Kadimastem to significantly narrow its operating losses while maintaining core operational viability. Comparison of the Years Ended December 31, 2023 and 2022 Revenues Kadimastem had no